Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBIT (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of EBIT data on record, last reported at -$17.1 million in Q4 2025.

  • For Q4 2025, EBIT changed 0.4% year-over-year to -$17.1 million; the TTM value through Dec 2025 reached -$68.1 million, down 33.72%, while the annual FY2025 figure was -$68.1 million, 33.73% down from the prior year.
  • EBIT reached -$17.1 million in Q4 2025 per CTNM's latest filing, down from -$14.9 million in the prior quarter.
  • Across five years, EBIT topped out at $38.9 million in Q2 2023 and bottomed at -$18.1 million in Q1 2025.
  • Average EBIT over 3 years is -$8.6 million, with a median of -$12.0 million recorded in 2024.
  • Peak YoY movement for EBIT: plummeted 128.11% in 2024, then fell 0.4% in 2025.
  • A 3-year view of EBIT shows it stood at -$9.7 million in 2023, then crashed by 76.18% to -$17.0 million in 2024, then decreased by 0.4% to -$17.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$17.1 million in Q4 2025, -$14.9 million in Q3 2025, and -$17.9 million in Q2 2025.